BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37024557)

  • 1. External beam radiotherapy combination is a risk factor for bladder cancer in patients with prostate cancer treated with brachytherapy.
    Minami T; Fujita K; Hashimoto M; Nishimoto M; Adomi S; Banno E; Nozawa M; Nose K; Yoshimura K; Inada M; Yokokawa M; Nakamatsu K; Uemura H
    World J Urol; 2023 May; 41(5):1317-1321. PubMed ID: 37024557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
    Moschini M; Zaffuto E; Karakiewicz PI; Andrea DD; Foerster B; Abufaraj M; Soria F; Mattei A; Montorsi F; Briganti A; Shariat SF
    Eur Urol; 2019 Feb; 75(2):319-328. PubMed ID: 30293908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of prostate cancer radiotherapy on the biological behavior and specific mortality of subsequent bladder cancer.
    Guo X; Liu M; Hou H; Liu S; Zhang X; Zhang Y; Wu P; Pang C; Wang J
    Int J Clin Oncol; 2019 Aug; 24(8):957-965. PubMed ID: 30903422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.
    Sandler KA; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Song DY; Klein EA; Stephenson AJ; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco SC; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR; Kishan AU
    Eur Urol; 2020 Jan; 77(1):3-10. PubMed ID: 30992160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer.
    Johnson SB; Lester-Coll NH; Kelly JR; Kann BH; Yu JB; Nath SK
    Eur Urol; 2017 Nov; 72(5):738-744. PubMed ID: 28688613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
    Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
    Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prognosis of Radical Prostatectomy, External Beam Radiotherapy plus Brachytherapy, and External Beam Radiotherapy Alone for Patients above 70 Years with Very High-Risk Prostate Cancer: A Population-Matched Study.
    Song P; Shu M; Yang L; Di X; Liu P; Liu Z; Zhou J; Dong Q
    Urol Int; 2022; 106(1):11-19. PubMed ID: 34515256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes and toxicities in patients with intermediate-risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy.
    Schlussel Markovic E; Buckstein M; Stone NN; Stock RG
    BJU Int; 2018 May; 121(5):774-780. PubMed ID: 29319919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary bladder cancer during long-term follow-up after iodine-125 permanent seed implantation for localized prostate cancer.
    Ozawa Y; Yagi Y; Nakamura K; Hattori S; Nishiyama T; Momma T; Yorozu A; Saito S
    Brachytherapy; 2022; 21(4):451-459. PubMed ID: 35461773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer.
    Zelefsky MJ; Housman DM; Pei X; Alicikus Z; Magsanoc JM; Dauer LT; St Germain J; Yamada Y; Kollmeier M; Cox B; Zhang Z
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):953-9. PubMed ID: 22172904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy.
    Andruska N; Agabalogun T; Fischer-Valuck BW; Brenneman RJ; Huang Y; Gay HA; Michalski JM; Carmona R; Baumann BC
    Brachytherapy; 2022; 21(5):617-625. PubMed ID: 35641370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
    Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival Outcomes of Dose-Escalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base.
    Amini A; Jones B; Jackson MW; Yeh N; Waxweiler TV; Maroni P; Kavanagh BD; Raben D
    J Urol; 2016 May; 195(5):1453-1458. PubMed ID: 26576709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base.
    Amini A; Jones BL; Jackson MW; Rusthoven CG; Maroni P; Kavanagh BD; Raben D
    Brachytherapy; 2016; 15(2):136-46. PubMed ID: 26825856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the role of external beam radiation therapy in combination with brachytherapy versus brachytherapy alone for unfavorable intermediate-risk prostate cancer.
    Andruska N; Michalski JM; Carmona R; Agabalogun T; Brenneman RJ; Gay HA; Fischer-Valuck BW; Baumann BC
    Brachytherapy; 2022; 21(3):317-324. PubMed ID: 35123889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of secondary bladder cancer developing after low-/high-dose-rate brachytherapy to treat localized prostate cancer.
    Miyajima K; Suzuki H; Urabe F; Iwatani K; Imai Y; Yasue K; Yanagisawa T; Kimura S; Tashiro K; Tsuzuki S; Koike Y; Miki J; Yuen S; Sasaki T; Aoki M; Sato S; Takahashi H; Miki K; Kimura T
    Int J Clin Oncol; 2023 Sep; 28(9):1200-1206. PubMed ID: 37432614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients.
    Bhojani N; Capitanio U; Suardi N; Jeldres C; Isbarn H; Shariat SF; Graefen M; Arjane P; Duclos A; Lattouf JB; Saad F; Valiquette L; Montorsi F; Perrotte P; Karakiewicz PI
    Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):342-8. PubMed ID: 20117287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
    Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
    JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence in intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT) dose escalation or low-dose rate (LDR) brachytherapy.
    Krishnan V; Delouya G; Bahary JP; Larrivée S; Taussky D
    BJU Int; 2014 Dec; 114(6):865-71. PubMed ID: 24274784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
    Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.